Novavax raised its full-year adjusted revenue forecast on Wednesday, banking on higher sales tied to its vaccine supply ...

The issuer is solely responsible for the content of this announcement.

The Department of Health and Human Services is terminating around $500 million in BARDA contracts associated with mRNA ...

The U.S. Department of Health and Human Services said it would wind down mRNA vaccine development activities under its biomedical research unit.

Second Quarter 2025 Results Key Financial Results Revenue: US$14.7b (up 10% from 2Q 2024).

From tariffs to drug pricing to the FDA, biopharma CEOs find themselves pulled into policy discussions on this year’s second quarter earnings calls.

The health secretary also announced that the department would reallocate the funds toward “safer, broader vaccine platforms ...

Q2 total revenue of $10.7M includes previously-deferred revenue following reacquisition of Greater China rights to ...

The twists and turns in U.S. President Donald Trump's tariff policies have not only roiled global financial markets but also ...

The US Department of Health and Human Services has decided to halt the contract and pull $500 million in funding for the mRNA ...